{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:27:26Z","timestamp":1787927246066,"version":"build-2784847793"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Obesity and type 2 diabetes now coexist with IBD. Beyond glucose and weight effects, GLP-1 receptor agonists reduce MACE and lower systemic inflammatory biomarkers. Observational IBD data suggest acceptable safety and fewer hospitalisations and surgeries, warranting carefully designed prospective trials.<\/jats:p>","DOI":"10.1177\/20420188261478400","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:53:01Z","timestamp":1787763181000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7172-4300","authenticated-orcid":false,"given":"Dured","family":"Dardari","sequence":"first","affiliation":[{"name":"Centre Hospitalier Sud Francilien"},{"name":"Universit\u00e9 D\u2019\u00c9vry, IRBA, Universit\u00e9 Paris-Saclay"},{"name":"Universit\u00e9 Paris-Saclay"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i12.1779"},{"issue":"2","key":"e_1_3_6_3_2","first-page":"otad015","article-title":"High Burden of Obesity and Low Rates of Weight Loss Pharmacotherapy in Inflammatory Bowel Disease: 10-Year Trend","volume":"5","author":"Elangovan A","year":"2023","unstructured":"Elangovan A, Shah R, Ali SMJ, et al. High Burden of Obesity and Low Rates of Weight Loss Pharmacotherapy in Inflammatory Bowel Disease: 10-Year Trend. Crohns Colitis 360 2023; 5(2): otad015. https:\/\/doi.org\/10.1093\/crocol\/otad007","journal-title":"Crohns Colitis 360"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/nutrit\/nuab028"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.06.036"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab097"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-022-04190-y"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019900660"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16366"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100979"},{"key":"e_1_3_6_14_2","first-page":"1134","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"59","author":"Desai A","year":"2024","unstructured":"Desai A, Petrov JC, Hashash JG, et al. Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease. Aliment Pharmacol Ther 2024; 59: 1134\u20131144. https:\/\/doi.org\/10.1111\/apt.18138","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae276"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf181"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194751"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.02.005"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15728"},{"key":"e_1_3_6_20_2","unstructured":"European Medicines Agency. Ozempic (semaglutide): summary of product characteristics. Accessed 2026-03-02."},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01392-3"}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188261478400","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188261478400","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188261478400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:43:42Z","timestamp":1787924622000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188261478400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"alternative-id":["10.1177\/20420188261478400"],"URL":"https:\/\/doi.org\/10.1177\/20420188261478400","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"20420188261478400"}}